Skip to content

Study · Non-randomized trial · 2021

4 results

On the road of dried blood spot sampling for antidoping tests: Detection of GHRP-2 abuse.

Reverter-Branchat G, Segura J, Pozo OJ

Drug testing and analysis25 Nov 2020Cited by 11 (Europe PMC)

PMID33197153 (opens in a new tab)DOI10.1002/dta.2975 (opens in a new tab)PepBankPUB-33197153
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialPharmacokinetics

    After a single intravenous dose of GHRP‑2 (100 μg) in an administration study, GHRP‑2 was detected in dried blood spots up to 4 h after injection.

    In plain wordsAfter one 100 μg intravenous dose, GHRP‑2 could be detected in dried blood spots for up to 4 hours.

    Peptide
    GHRP-2
    Outcome
    Not applicableDetection window after intravenous GHRP-2
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    100 μg · intravenous · single doseAs given in this study (human).

    Measurements

    Detection time
    ≤ 4 h
    after intravenous GHRP-2 100 μg

    Source sentences

    Summary
    The procedure has been successfully applied to actual DBS samples from an administration study with a single intravenous dose of GHRP-2 (100 μg) being detected up to 4 h after drug injection.
    1 context sentence
    Summary · context
    Here, GHRP-2 has been selected as a representing member of the growth hormone-releasing peptides (GHRPs) family to provide further evidence of DBS suitability for GHRPs abuse detection in sport testing.
  2. 02HumanNon-randomized trialPharmacokinetics

    In the administration study, GHRP‑2 concentrations were higher in venous blood spots than in capillary blood spots, with a similar detection window in both.

    In plain wordsGHRP‑2 levels were higher in venous than in capillary blood spots, but both showed a similar detection time.

    Peptide
    GHRP-2
    Outcome
    IncreaseGHRP-2 concentration in venous versus capillary blood spots
    Study

    n: not reported in source

    Comparator
    Capillary blood DBS
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    100 μg · intravenous · single doseAs given in this study (human).

    Source sentences

    Summary
    GHRP-2 concentrations have been higher in venous blood DBS than in capillary blood DBS. Despite the observed differences, a similar detection window has been achieved independently of the type of blood used.
    1 context sentence
    Summary · context
    Here, GHRP-2 has been selected as a representing member of the growth hormone-releasing peptides (GHRPs) family to provide further evidence of DBS suitability for GHRPs abuse detection in sport testing.

Studies that did not test the peptide alone2

In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-2.

  1. 03LabNot a test of GHRP-2 aloneOther designOther

    An LC-MS/MS method for dried blood spots detected GHRP‑2 with a limit of detection of 50 pg/ml.

    In plain wordsIn lab tests, a dried blood spot method detected GHRP‑2 down to 50 pg/ml. This is an assay result, not a drug effect.

    Peptide
    GHRP-2
    Outcome
    Not applicableLimit of detection of GHRP-2 in dried blood spots
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    LoD
    50 pg/ml
    GHRP-2 in dried blood spots

    Source sentences

    Summary
    An analytical procedure to extract GHRP-2 and its main metabolite (AA-3) from DBS and to detect them by liquid chromatography-tandem mass spectrometry (LC-MS/MS) has been developed.
    2 context sentences
    Summary · context
    The limit of detection (LoD) for GHRP-2 has been established at 50 pg/ml.
    Summary · context
    Here, GHRP-2 has been selected as a representing member of the growth hormone-releasing peptides (GHRPs) family to provide further evidence of DBS suitability for GHRPs abuse detection in sport testing.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  2. 04LabNot a test of GHRP-2 aloneOther designOther

    Long-term stability of GHRP‑2 in dried blood spots was confirmed for more than 2 years.

    In plain wordsIn lab tests, GHRP‑2 stayed stable in dried blood spots for more than 2 years.

    Peptide
    GHRP-2
    Outcome
    Not applicableLong-term stability of GHRP-2 in dried blood spots
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    Stability
    > 2 years
    dried blood spots

    Source sentences

    Summary
    Long-term stability (>2 years) has been confirmed.
    1 context sentence
    Summary · context
    Here, GHRP-2 has been selected as a representing member of the growth hormone-releasing peptides (GHRPs) family to provide further evidence of DBS suitability for GHRPs abuse detection in sport testing.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.